CU20150067A7 - 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio y sales farmacéuticamente aceptables para tratar la ateroclerosis - Google Patents

3-carboxi-n-etil-n,n-dimetilpropan-1-aminio y sales farmacéuticamente aceptables para tratar la ateroclerosis

Info

Publication number
CU20150067A7
CU20150067A7 CUP2015000067A CU20150067A CU20150067A7 CU 20150067 A7 CU20150067 A7 CU 20150067A7 CU P2015000067 A CUP2015000067 A CU P2015000067A CU 20150067 A CU20150067 A CU 20150067A CU 20150067 A7 CU20150067 A7 CU 20150067A7
Authority
CU
Cuba
Prior art keywords
pharmaceutically acceptable
acceptable salts
dimetilpropan
ateroclerosis
carboxi
Prior art date
Application number
CUP2015000067A
Other languages
English (en)
Spanish (es)
Inventor
Ivars Kalvins
Reinis Vilskersts
Osvalds Pugovics
Maija Dambrova
Ilmars Stonans
Janis Kuka
Edgars Liepins
Einars Loza
Viktors Andrianovs
Solveiga Grinberga
Daina Gustina
Daina Lola
Marina Makrecka
Original Assignee
Grindeks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks filed Critical Grindeks
Publication of CU20150067A7 publication Critical patent/CU20150067A7/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CUP2015000067A 2012-12-20 2015-06-19 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio y sales farmacéuticamente aceptables para tratar la ateroclerosis CU20150067A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12198627 2012-12-20
PCT/EP2013/077291 WO2014096133A1 (en) 2012-12-20 2013-12-19 Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
CU20150067A7 true CU20150067A7 (es) 2016-01-29

Family

ID=47458734

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000067A CU20150067A7 (es) 2012-12-20 2015-06-19 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio y sales farmacéuticamente aceptables para tratar la ateroclerosis

Country Status (11)

Country Link
CN (1) CN104869988B (ar)
AR (1) AR094084A1 (ar)
BR (1) BR112015014161B1 (ar)
CA (1) CA2895574C (ar)
CU (1) CU20150067A7 (ar)
JO (1) JO3117B1 (ar)
MX (1) MX362762B (ar)
PE (1) PE20151587A1 (ar)
TN (1) TN2015000236A1 (ar)
WO (1) WO2014096133A1 (ar)
ZA (1) ZA201505093B (ar)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149654A1 (en) * 2009-06-25 2010-12-29 Grindeks, A Joint Stock Company Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt
BRPI1009600A2 (ar) * 2009-06-25 2016-03-22 Tetra S A
LV14345B (lv) * 2009-10-22 2011-07-20 Grindeks, A/S 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai
BR112013027065B1 (pt) * 2011-04-27 2019-12-03 Grindeks Jsc processo para a preparação de sais de 3-carboxi-n-etil-n,n-dimetilpropan-1amínio, compostos e seus usos

Also Published As

Publication number Publication date
BR112015014161A2 (pt) 2017-07-11
MX2015008138A (es) 2016-04-25
JO3117B1 (ar) 2017-09-20
ZA201505093B (en) 2016-04-28
CA2895574C (en) 2019-11-26
CA2895574A1 (en) 2014-06-26
BR112015014161B1 (pt) 2021-02-17
MX362762B (es) 2019-02-06
CN104869988B (zh) 2017-07-28
AR094084A1 (es) 2015-07-08
WO2014096133A1 (en) 2014-06-26
PE20151587A1 (es) 2015-12-05
TN2015000236A1 (en) 2016-10-03
CN104869988A (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PY1212975A (es) Compuestos de azabiclo o quinuclidin-carbamato como inhibidores de glucosilceramida sintasa
DOP2014000064A (es) Compuestos 1-arilcarbonil-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas
GT201500051A (es) Inhibidores de glucosilceramida sintasa
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
MX2015011273A (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacio nados con la fosfoinositida 3-cinasa delta.
UY33910A (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
ECSP16073171A (es) Ciclopropilaminas como inhibidores de lsd1
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CR20130023A (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
BR112013025415A2 (pt) métodos para aumentar eficácia de terapia de câncer de folr1
CO7180199A2 (es) Imidazotriazincarbonitrilos útiles como inhibidores de cinasa
BR112015000399A2 (pt) derivados de pirazolil pirimidina
CR20150425A (es) Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes
MX2015012427A (es) Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
CU24335B1 (es) Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
CR20200177A (es) Compuestos de biheteroarilo (divisional 2015-0589)
ES2570976T3 (es) Derivado de 2,4-diaminopirimidina bicíclico condensado como inhibidor dual de ALK y FAK
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CR20150211A (es) Compuestos diméricos